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Abstract
Background: Nail-patella syndrome (NPS) is an autosomal dominant disorder caused by mutations in the LMX1B
gene and is characterized by nail dysplasia, skeletal abnormalities, and nephropathy. We herein report a case of
steroid-resistant nephrotic syndrome (SRNS) prior to overt orthopedic symptoms in a patient with NPS.
Case presentation: A 24-year-old woman presented to our hospital with knee pain. She had poorly developed
nails, hypoplastic patellas, dislocation of the elbows, and iliac horns in the pelvis. At the age of 7, she developed
nephrotic syndrome and was diagnosed with primary focal segmental glomerulosclerosis by renal biopsy. She
received long-term corticosteroid therapy with no obvious response. Her clinical course and orthopedic
manifestations indicated NPS, and a genetic analysis showed a de novo mutation in the LMX1B gene (c.819 + 1G >
A). Nephropathy in this case was considered to be associated with NPS. Therefore, we discontinued corticosteroids
without the exacerbation of nephrotic syndrome.
Conclusions: Patients with NPS may develop nephrotic syndrome prior to overt orthopedic symptoms and only
show non-specific findings in renal biopsy at an early stage of NPS nephropathy. Hereditary nephrotic syndrome,
often presenting as childhood-onset SRNS, may also be difficult to diagnose in patients with the following
conditions: renal symptoms prior to overt extrarenal symptoms, de novo mutations, and non-specific findings in
renal biopsy. Therefore, in the management of SRNS in children, we need to reconsider the possibility of hereditary
diseases such as NPS even without a family history.
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Background
Nail-patella syndrome (NPS; OMIM 161200) is a pleio-
tropic autosomal dominant disorder characterized by
nail dysplasia, patellar aplasia or hypoplasia, elbow
dysplasia, and iliac horns in the pelvis [1–3]. The
causative gene of NPS has been identified as the LIM
homeobox transcription factor 1 beta (LMX1B; OMIM
602575) gene, which is located on the long arm of
chromosome 9 [4]. The incidence of NPS was previously
reported to be approximately 1:50,000, with de novo
mutations accounting for 12.5% of NPS cases [4, 5].
Nail anomalies have been detected in 95.1% of NPS
patients, patellar aplasia or hypoplasia in 92.7%, iliac
horns in 70%–80%, elbow dysplasia in 92.5%, ocular
hypertension in 7%, and glaucoma in 10% [3]. The
incidence of renal involvement was found to be 37.5% in
NPS patients, and the mean age when renal involvement
was detected was 21.7 years [2]. Nephrotic syndrome is
exceptional; most patients present with proteinuria and
hematuria [2, 6]. Renal failure occurs in between 5 and
14% of NPS patients [2].
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We herein report a case of childhood-onset steroid-
resistant nephrotic syndrome (SRNS) that was diagnosed
with NPS based on delayed orthopedic symptoms and a
genetic analysis following long-term corticosteroid ther-
apy. We also discuss the need to reconsider hereditary
diseases in the management of children with SRNS even
without a family history.
Case presentation
A 24-year-old woman presented to our hospital with
pain in her knee. At the age of seven, she developed
nephrotic syndrome and was diagnosed with primary
focal segmental glomerulosclerosis (FSGS) by renal bi-
opsy (Fig. 1). Nephrotic syndrome gradually worsened
without symptoms such as edema. She was administered
corticosteroids from the age of 18 years, but did not
respond to this therapy. Cyclosporine was then adminis-
tered, but was discontinued within one week due to the
adverse effect of fatigue. Corticosteroids were tapered
with proteinuria of 4 to 6 g per 24 hours.
When she presented to our hospital, she had poorly
developed nails and small corneas. Intraocular pressure
was normal. She gradually developed pain in her knee
over 12 months. X-ray and computed tomography were
performed to systemically evaluate the orthopedic
morphology, and revealed hypoplastic patellas, disloca-
tion of the elbows, and iliac horns in the pelvis (Fig. 2).
Laboratory data showed hypoalbuminemia and the
excretion of a large amount of protein in the urine, indi-
cating nephrotic syndrome with renal insufficiency.
Other serological results revealed that the secondary
causes of nephrotic syndrome such as autoimmune dis-
ease, hematological diseases, or infection were negative
(Table 1). Her clinical course of SRNS and orthopedic
manifestations indicated NPS; therefore, we performed a
genetic analysis, which showed a heterozygous mutation
in the first base of the fifth intron of the LMX1B gene
(c.819 + 1G > A) (Fig. 3). Since this mutation was not
detected in her parents, our case was considered to have
a de novo mutation.
Fig. 1 Renal biopsy at the age of 7. Light microscopy only showed focal glomerular lesions (a) Periodic-Acid Schiff stain x400, (b) Periodic
acid-methenamine-silver stain x400). Immunofluorescence showed slightly positive staining for IgM and C3 within glomerular segmental lesions
(c). Electron microscopy revealed mild irregular thickening of the GBM and swollen podocytes (# in d) with partial foot process effacement
(arrowhead in d). Neither electron-lucent areas within the GBM nor electron-dense deposits were detected (d)
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In a review of renal biopsy at the age of 7, light
microscopy revealed focal glomerular lesions only
(Fig. 1a-b). Immunofluorescence showed slightly positive
staining for IgM and C3 within glomerular segmental
lesions (Fig. 1c). Electron microscopy displayed mild
irregular thickening of the glomerular basement mem-
brane (GBM) and swollen podocytes with partial foot
process effacement, whereas distinctive lesions such as
electron-lucent areas within the GBM were not detected
(Fig. 1d). Although we were unable to perform renal
biopsy again because of renal atrophy (parenchymal
thinning, an indistinct corticomedullary junction, and
longitudinal length of 9 cm by ultrasonography),
nephropathy in this case was considered to be associated
with NPS. Therefore, we discontinued corticosteroids
gradually without the exacerbation of nephrotic
syndrome.
Discussion
NPS is an autosomal dominant disorder characterized by
orthopedic manifestations. In our case, NPS was difficult
to diagnose early for the following reasons: 1) nephrotic
syndrome developed prior to overt orthopedic symp-
toms; 2) she had no family history; and 3) renal
pathology revealed only non-specific findings in the
GBM at an early stage of NPS nephropathy. Based on
the presence of orthopedic symptoms, we performed a
genetic analysis, detected a de novo mutation in LMX1B
without this mutation in her parents, and discontinued
unnecessary steroid treatments.
Fig. 2 Nail abnormalities and orthopedic manifestations at the age of 24. She presented with poorly developed nails (a). An x-ray examination
revealed hypoplastic patellas (b), dislocation of the elbows (c), and iliac horns in the pelvis (d)
Table 1 Laboratory data on admission




RBC 515 × 104/μl Rheumatoid factor Negative
Hb 14.8 g/dl IgG 323 mg/dl
Ht 42.9% IgA 179 mg/dl
Plt 43.3 × 104/μl IgM 259 mg/dl
Blood chemistry C3 80.5 mg/dl
TP 4.8 g/dl C4 14.6 mg/dl
Alb 2.8 g/dl CH50 35.0 U/ml
AST 11 IU/ml C1q Negative
ALT 14 IU/ml HBs antigen Negative
LDH 240 IU/ml Anti-HCV antibody Negative
BUN 12.1 mg/dl Urinalysis
Cr 1.01 mg/dl Gravity 1.013
eGFR 45 ml/min/1.73 m2 pH 6.5
Na 140 mEq/l Protein 4+
K 3.6 mEq/l Occult blood -
Cl 105 mEq/l Sediments
LDL 123 mg/dl RBC <1/HPF
TG 157 mg/dl
HbA1c 5.2% Urinary chemistry
CRP 0.01 mg/dl Protein 7.67 g/gCr
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LMX1B is expressed in the dorsal mesenchyme of de-
veloping vertebrate limbs and plays a critical role in the
patterning of the dorsal-ventral axis [7]. Once the
dorsal-ventral axis is established, LMX1B activates the
expression of a number of dorsalizing genes, suppresses
the expression of ventralizing genes, and modulates the
development of dorsal distal limb structures such as
nails and patellas [4]. In addition to limb development,
the LMX1B gene is associated with the development of
multiple organs such as the brain, spinal cord, eyes, ears,
and kidneys [8, 9]. In our case, this gene mutation was
implicated in the impairments observed in the limbs,
nails, and eyes as extrarenal symptoms.
The expression of LMX1B in the kidney was initially
detected in the region of the S-shaped body, which gives
rise to the glomerulus, and subsequently in the visceral
epithelium of the glomerulus in experiments on mice
[4]. LMX1B binds to an enhancer sequence in intron 1
of the collagen IV α4 chain and regulates the coordi-
nated expression of collagen IV α3 and α4 chains, which
are required for normal GBM morphogenesis [10]. A
previous study on heterozygous LMX1B knockout mice
demonstrated that LMX1B affects increases in glomeru-
lar volume as a compensatory response to the loss of
nephrons [11]. Other studies on podocyte-specific
LMX1B conditional knockout mice demonstrated that
LMX1B is required for the initial differentiation of podo-
cytes and development of foot processes [12, 13]. In
addition, LMX1B is considered to bind to sites in the
putative regulatory regions of the CD2AP and NPHS2
genes and regulate their expression, which is associated
with the formation of the slit diaphragm [13].
More than 140 mutations have been detected in
LMX1B, and the mutation in our case was previously
reported to result in the loss of function of LMX1B due
to a dysfunction in exon 6 [14]. Although comparisons
of phenotypes with genotypes have not revealed any re-
lationship between disease severity and the type or loca-
tion of mutations [14], specific missense mutations in
LMX1B have recently been identified in cases of
nephropathy without extrarenal manifestations [15, 16].
In the present case, nephrotic syndrome developed at
the age of 7, followed by overt orthopedic symptoms
after the growth period. Therefore, our case is clearly
distinguishable from previously reported cases of
isolated nephropathy caused by LMX1B mutations.
The renal pathological findings of NPS nephropathy
vary from minor glomerular abnormalities to FSGS
under light microscopy [17], and irregular increases in
the thickness of the GBM are observed with the progres-
sion of the disease. Immunofluorescence is typically
negative or IgM and C3 are slightly positive within
glomerular segmental lesions. In addition, electron mi-
croscopy shows irregular thickening of the GBM with
electron-lucent areas, which is known as the moth-eaten
appearance. The deposition of collagen III has been de-
tected in GBM lesions [17]. However, the extent and dis-
tribution of GBM lesions vary individually without any
relationship with the age of patients or severity of renal
symptoms [17]. Thus, non-specific pathological findings
may be observed at an early stage of NPS nephropathy.
In our case, only focal segmental glomerular lesions and
mild irregular thickening of the GBM without electron-
lucent areas were detected. Consequently, she was not
Fig. 3 Genetic analysis. The genetic analysis showed a heterozygous mutation in the first base of the fifth intron (c.819 + 1G > A) of the LMX1B
gene located on the long arm of chromosome 9. The same mutation was not detected in her parents
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diagnosed with NPS at the age of 7, and received im-
munosuppressive therapy. Renal involvement in NPS is
caused by a LMX1B gene mutation, which dysregulates
the production of collagen, and corticosteroids have no
effect on this gene mutation. Thus, her clinical course
with no response to corticosteroids supported the diag-
nosis of NPS. There are currently no specific treatments
for renal involvement in NPS, except for angiotensin-
converting enzyme inhibitors, which reduce proteinuria
in NPS patients [5]. Therefore, we discontinued cortico-
steroids without the exacerbation of nephrotic
syndrome.
Conclusions
Patients with NPS may develop nephrotic syndrome
prior to overt orthopedic symptoms and only show non-
specific findings in renal biopsy at an early stage of NPS
nephropathy. Additionally, hereditary nephrotic syn-
drome, often presenting as childhood-onset SRNS, may
be difficult to diagnose in patients with the following
conditions: renal symptoms prior to overt extrarenal
symptoms, de novo mutations, and non-specific findings
in renal biopsy. Therefore, in the management of SRNS
in children, we need to reconsider the possibility of
hereditary diseases such as NPS even without a family
history.
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